A Phase 1b/2 Open-Label Trial of Tisotumab Vedotin (HuMax® ®-TF -ADC) in Combination with Other Agents in Subjects with Recurrent or Stage IVB Cervical Cancer

Sponsor: Genmab

Participating sites:

  • UZ Leuven, Leuven
  • CHU de Liège, site Sart Tilman, Liège
  • UZ Antwerpen, Antwerpen
  • CHU UCL St-Luc, Bruxelles
  • Grand Hôpital de Charleroi, Charleroi
  • CHU UCL St-Luc, Bruxelles
  • AZ Sint-Jan Brugge, Brugge
  • UZ Gent, Gent
  • Hôpital de Libramont, Libramont